Research Analysts Issue Forecasts for TCRX FY2026 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Investment analysts at Wedbush decreased their FY2026 earnings per share estimates for TScan Therapeutics in a report issued on Tuesday, December 10th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.97) per share for the year, down from their previous estimate of ($0.96). Wedbush currently has a “Outperform” rating and a $7.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics’ FY2027 earnings at ($1.02) EPS and FY2028 earnings at ($0.94) EPS.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The business had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million.

Other research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a report on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a research report on Wednesday.

TScan Therapeutics Price Performance

Shares of NASDAQ TCRX opened at $2.85 on Friday. The company has a fifty day moving average price of $4.82 and a 200 day moving average price of $5.87. The firm has a market cap of $152.10 million, a PE ratio of -2.69 and a beta of 0.79. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a 1-year low of $2.60 and a 1-year high of $9.69.

Insider Buying and Selling

In other TScan Therapeutics news, Director Barbara Klencke bought 5,000 shares of TScan Therapeutics stock in a transaction on Monday, September 23rd. The shares were purchased at an average cost of $5.29 per share, with a total value of $26,450.00. Following the acquisition, the director now directly owns 45,000 shares of the company’s stock, valued at $238,050. The trade was a 12.50 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.76% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TCRX. Bank of Montreal Can acquired a new stake in TScan Therapeutics during the 2nd quarter worth about $749,000. Bank of New York Mellon Corp bought a new stake in shares of TScan Therapeutics during the 2nd quarter valued at about $682,000. Great Point Partners LLC acquired a new stake in TScan Therapeutics during the second quarter worth approximately $5,504,000. Marshall Wace LLP increased its holdings in TScan Therapeutics by 60.8% in the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock worth $1,799,000 after purchasing an additional 116,316 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in TScan Therapeutics in the second quarter valued at approximately $90,000. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.